Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767436 | 1.00 | SPHK1 (0.47) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL16421029 | 0.88 | SPHK1 (0.46) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL15209132 | 0.87 | SPHK1 (0.48) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL15209134 | 0.87 | SPHK1 (0.48) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL17244141 | 0.86 | SPHK1 (0.48) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL14704757 | 0.86 | SPHK1 (0.49) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL13110172 | 0.86 | SPHK1 (0.49) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL5063645 | 0.86 | SPHK1 (0.49) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL1526136 | 0.84 | SPHK1 (0.50) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL20621505 | 0.84 | SPHK1 (0.53) | SPHK1HSD11B2BRD4CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214554-B2 | Indoleamine 2,3-dioxygenase inhibitor, method for preparation and use thereof | NANJING HUAWE MEDICINE TECHNOLOGY GROUP CO., LTD. (CN) | 2022-01-04 | — | — | US | disclosed |
| US-20210094924-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, METHOD FOR PREPARATION AND USE THEREOF | NANJING HUAWE MEDICINE TECHNOLOGY GROUP CO., LTD. (CN) | 2021-04-01 | — | — | US | disclosed |
| WO-2019141027-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | 南京华威医药科技集团有限公司 | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094924-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, METHOD FOR PREPARATION AND USE THEREOF | IDO1, IDO2, KYNU | SPHK1 2792/4885HSD11B2 247/4885BRD4 2905/4885 |
| US-11214554-B2 | Indoleamine 2,3-dioxygenase inhibitor, method for preparation and use thereof | IDO1, IDO2, KYNU | SPHK1 2021/4885HSD11B2 162/4885BRD4 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.